NasdaqCM - Delayed Quote USD

Pluri Inc. (PLUR)

Compare
5.41 +0.21 (+4.04%)
At close: 4:00 PM EDT
5.15 -0.26 (-4.81%)
After hours: 4:20 PM EDT
Loading Chart for PLUR
DELL
  • Previous Close 5.20
  • Open 5.14
  • Bid --
  • Ask --
  • Day's Range 5.12 - 5.42
  • 52 Week Range 3.44 - 8.48
  • Volume 3,467
  • Avg. Volume 8,273
  • Market Cap (intraday) 29.594M
  • Beta (5Y Monthly) 1.60
  • PE Ratio (TTM) --
  • EPS (TTM) -3.99
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

www.pluri-biotech.com

106

Full Time Employees

June 30

Fiscal Year Ends

Recent News: PLUR

View More

Performance Overview: PLUR

Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PLUR
16.59%
S&P 500
19.50%

1-Year Return

PLUR
22.95%
S&P 500
32.92%

3-Year Return

PLUR
73.38%
S&P 500
30.82%

5-Year Return

PLUR
81.82%
S&P 500
97.39%

Compare To: PLUR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PLUR

View More

Valuation Measures

Annual
As of 10/2/2024
  • Market Cap

    28.99M

  • Enterprise Value

    28.62M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    85.19

  • Price/Book (mrq)

    301.99

  • Enterprise Value/Revenue

    87.79

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.67%

  • Return on Equity (ttm)

    -206.07%

  • Revenue (ttm)

    326k

  • Net Income Avi to Common (ttm)

    -20.89M

  • Diluted EPS (ttm)

    -3.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.98M

  • Total Debt/Equity (mrq)

    546.85%

  • Levered Free Cash Flow (ttm)

    -12.82M

Research Analysis: PLUR

View More

Revenue vs. Earnings

Revenue 96k
Earnings -5.73M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: PLUR

People Also Watch